"
Team:Freiburg/Results/Summary
From 2014.igem.org
| (One intermediate revision not shown) | |||
| Line 23: | Line 23: | ||
</div> | </div> | ||
<aside> | <aside> | ||
| - | + | </html>{{:Team:Freiburg/Results/asidenav}}<html> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
</aside> | </aside> | ||
</div> | </div> | ||
| Line 43: | Line 35: | ||
{{:Team:Freiburg/Templates/html/js.html}} | {{:Team:Freiburg/Templates/html/js.html}} | ||
<html> | <html> | ||
| + | <script> | ||
| + | // hover over effects | ||
| + | (function(){ | ||
| + | var left = $('#over-left'), | ||
| + | right = $('#over-right'), | ||
| + | links = $('#svg-schema-overview svg a'); | ||
| + | console.dir(links); | ||
| + | function onHover(){ | ||
| + | console.log("hovering"); | ||
| + | // grab content | ||
| + | var content = $($(this).data('id')); | ||
| + | |||
| + | // set content | ||
| + | var target = content.data('target'); | ||
| + | console.dir(content); | ||
| + | console.dir(target); | ||
| + | if (target == '#over-right') right.html(content.html()); | ||
| + | if (target == '#over-left') left.html(content.html()); | ||
| + | }; | ||
| + | |||
| + | function onBlur(){ | ||
| + | // clear content | ||
| + | right.html(''); | ||
| + | left.html(''); | ||
| + | } | ||
| + | |||
| + | // add hover/blur handler | ||
| + | links.hover(onHover, onBlur); | ||
| + | })(); | ||
| + | </script> | ||
<script> | <script> | ||
// set title | // set title | ||
Latest revision as of 21:26, 17 October 2014
Summary
We, the iGEM Team Freiburg 2014, have the goal to combine the capability of viral vectors for stable gene transfer with the spatio-temporal resolution of optogenetics for gene delivery into mammalian cells. We utilized the Murine Leukemia Virus (MuLV) that specifically uses the murine mCAT-1 receptor to infect target cells. By using a blue light inducible expression system, we brought the receptor to the plasma membrane of illuminated cells to enable targeted gene delivery by the virus.
Our project was quite a large success! We:
- produced MuLV viruses containing different reporter proteins,
- optimized MuLV production and transduction protocols to reach close to 100% efficiency,
- created stable mammalian cell lines using the MuLV virus,
- generated patterns of reporter proteins in cell cultures by light exposure,
- demonstrated that the virus exclusively infects cells expressing the mCAT-1 receptor,
- infected cells with the MuLV virus that expressed the mCAT-1 receptor after light induction.
We provide the virus as a tool for the generation of stable mammalian cell lines under biosafety level 1 regulations. Our viral vector, which we propose as a new iGEM RFC, enables the user to introduce any gene of interest stably into mammalian cell lines. Therefore we provide for the iGEM community a fast, easy to handle and safe way of generating stable cell lines.
During the course of iGEM, we learned many new techniques:
- mammalian cell culture,
- fluorescence activated cell sorting,
- virus production under biosafety level 1 and biosafety level 2 conditions,
- many different cloning techniques,
- widefield and confocal microscopy,
- creating a website,
and, last but not least, we had a lot of fun and learned how to work together as a team!
